When administered with LD chemotherapy and IL-2, mesothelin CAR-T cells have been associated with progressive disease (PD) in 14/15 patients with mesothelin-positive tumours at 3.5 months (NCT01583686; Table 1). Here, MSLN is linked to neoplasm.